Food Safety

The California Farm Bureau Federation is calling for FDA to rewrite all Food Safety Modernization Act (FSMA) rules, but it takes particular issue with the produce safety rule, which the group says unfairly subjects high- and low-risk produce to the same standards and is overly vague.

Consumer groups and private laboratories are waiting with bated breath for FDA to get a Food Safety Modernization Act (FSMA)-mandated lab accreditation program, which would certify private laboratories for analyzing food imports, off the ground.

Fast casual chain Panera is petitioning FDA to define egg in its regulations and bar eggs with added ingredients or processing from being called such.

The House Energy & Commerce oversight subcommittee will hold a hearing Friday (Jan. 19) on FDA’s handling of food recalls. The hearing will discuss a recently released report by the HHS Office of Inspector General, which identified key flaws in FDA’s response to food borne outbreaks.

In 2018, FDA will focus on making the process for developing and approving biosimilar drugs more efficient, modernizing its own internal processes and technologies, and developing a comprehensive plan to encourage development of healthy foods, the agency announced in its 2018 Strategic Policy Roadmap released on Thursday (Jan. 11).

In response to comments from food industry stakeholders, FDA won’t subject certain entities and activities to some provisions of the Food Safety Modernization Act (FSMA) that pertain to current good manufacturing practices (CGMPs) and risk-based controls for human and animal food; foreign supplier verification; and produce safety standards for growing, harvesting, packing and holding produce intended for humans, the agency explained in guidance document and press announcement on Thursday (Jan. 4).

FDA issued long-awaited guidance answering industry questions about how to comply with its menu labeling rule, slated to go into effect May 7, 2018, but the industry noted it will exercise enforcement discretion for out-of-compliance companies to help them comply with the law.

The ranking Democrat on the Senate health committee Monday (Oct. 16) slammed FDA Commissioner Scott Gottlieb's proposal to delay implementation of the agency's updated nutrition facts rule, saying the move is detrimental to public health and creates uncertainty for industry and consumers.

FDA's top lawyers argue that the U.S. International Trade Commission should not take up a recent unfair competition case filed by Amarin Pharma asking the commission to block importation and essentially freeze U.S. inventory of certain synthetic omega-3 products being sold as dietary supplements.